NBSE(Delisted)
NeuBase TherapeuticsยทNASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NBSE
Neubase Therapeutics, Inc.
A pre-clinical stage biopharmaceutical company that developing therapies for rare genetic diseases and cancers caused by mutant genes
350 Technology Drive, Pittsburgh, PA 15219
--
NeuBase Therapeutics, Inc. Incorporated in Delaware on August 4, 2009. This is a biotech company that uses a new synthetic drug to accelerate the genetic revolution. Their platform for modular peptide nucleic acid antisense oligonucleotide output "anti-gene" candidate therapies is designed to combine the specificity of target recognition based on gene sequences with modularity that allows the use of various in vivo delivery technologies to achieve broad and selective tissue distribution capabilities. Considering that every human disease may have a genetic component, their differentiated platform technology has the potential to have a broad impact, addressing disease progression for specific indications by increasing, decreasing or altering gene function at the DNA or RNA level.
Company Financials
EPS
NBSE has released its 2023 Q3 earnings. EPS was reported at -2.04, versus the expected 0, missing expectations. The chart below visualizes how NBSE has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
